MATTERHORN Trial Findings
Research reveals perioperative immunotherapy with Imfinzi addresses unmet needs in gastric and GEJ cancers.
Nancy Ghattas, VP at AstraZeneca, discusses the Phase III MATTERHORN trial results, highlighting a 22% reduction in death risk.
Imfinzi-based perioperative regimen improved overall survival regardless of PD-L1 status.
This marks the first immunotherapy to show such benefit in this setting, paving the way for a new standard of care.
Author's summary: New trial findings shift gastric cancer care.